Investors
- Board of Directors
- Board Meeting
- AGM Notice
- EGM Notice
- Closure Of Trading Window
- Related Party Transactions
- Share Holding Patterns
- Quarterly Results
- Annual Report
- Annual Return
- Secretarial Compliance
- Disclosure U/r 30
- Voting Results
- Newspaper Publications
- Insider Trading Code
- Investors-2
Mail to: companysec@indswift.com[Email id of designated official for the purpose of grievance redressal]
Unaudited Financial Results for the Quarter ended 30th June, 2004 |
|||
|---|---|---|---|
PARTICULARS |
QUARTER ENDED 30.06.04 (Unaudited) |
QUARTER ENDED 30.06.03 (Unaudited) |
YEAR ENDED 31.03.04 (Provisional) |
| INCOME FROM OPERATIONS | 5794.19 | 4904.08 | 21185.17 |
| OTHER INCOME | 11.92 | 8.51 | 114.12 |
| TOTAL INCOME | 5806.011 | 4912.59 | 21299.29 |
| TOTAL EXPENDITURE | 5399.95 | 4568.68 | 19661.41 |
| DECREASE IN STOCK IN trADE | 275.61 | 25.46 | -1784.71 |
| CONSUMPTION OF RAW MATERIAL | 4096.83 | 3681.07 | 17951.14 |
| COST OF SALES | 4372.44 | 3706.53 | 16166.43 |
| STAFF COST | 181.56 | 150.62 | 654.11 |
| OTHER EXPENSES | 666.24 | 524.82 | 2216.65 |
| INTEREST | 149.35 | 164.24 | 526.58 |
| DEPRECIATION | 30.36 | 22.47 | 97.64 |
| PROFIT BEFORE TAX | 406.16 | 343.91 | 1637.88 |
| PROVISION FOR TAX | 30.46 | 25.79 | 122.84 |
| PROVISION FOR DEFERRED TAX | 1.04 | 13.36 | 122.62 |
| NET PROFIT | 374.66 | 304.76 | 1392.42 |
| PAID UP SHARE CAPITAL | 502.5 | 439.5 | 462.5 |
| RESERVE EXCLUDING REVALUATION RESERVE | |||
| E.P.S.(Rs.) | 7.46 | 6.93 | 30.11 |
NOTES: |
|||
| 1. During the quarter under review the net profit rose by 23% and the Income from operation rose by 18% as compared to the corresponding quarter of the previous year. 2. An Anti-Diarroheal drug 'Nitazoxanide' was launched for the first time in India after the successful clinical trials . 3. To cater to the Regulated markets, a new manufacturing facility confirming to FDA standards is under progress. 4. Company has filed 45 dossiers with various Countries and export to those Countries have started. 5. During the Quarter revenue from C-R-A-M-S business accounted for 31% of the Company's net profit. 6. The Board has allotted 10,90,674 equity shares to the shareholders of two companies viz. Mukur Pharmaceutical Co. Pvt. Ltd. and Swift Formulations Pvt. Ltd. consequent to the merger of these Companies with Ind-Swift limited. 7. The Company is exclusively in the Pharmaceutical business segment. 8. The company had received 3 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 30th June, 2004. 9. The above financial results were taken on record by the Board at its meeting held on 28th July, 2004. |
|||
On behalf of the Board |
|||
Dated: 28.07.2004 |
(Gopal Munjal) |
||
Place: Chandigarh |
Chairman |
||